TANGO THERAPEUTICS INC (TNGX) Fundamental Analysis & Valuation

NASDAQ:TNGX • US87583X1090

12.35 USD
+0.85 (+7.39%)
At close: Mar 4, 2026
12.35 USD
0 (0%)
After Hours: 3/4/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This TNGX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

4

Overall TNGX gets a fundamental rating of 4 out of 10. We evaluated TNGX against 520 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for TNGX as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, TNGX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

1

1. TNGX Profitability Analysis

1.1 Basic Checks

  • TNGX had negative earnings in the past year.
  • TNGX had a negative operating cash flow in the past year.
  • TNGX had negative earnings in each of the past 5 years.
  • TNGX had a negative operating cash flow in each of the past 5 years.
TNGX Yearly Net Income VS EBIT VS OCF VS FCFTNGX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

  • TNGX has a Return On Assets (-47.83%) which is in line with its industry peers.
  • TNGX has a Return On Equity (-62.81%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -47.83%
ROE -62.81%
ROIC N/A
ROA(3y)-30.42%
ROA(5y)-20.6%
ROE(3y)-49.57%
ROE(5y)-33.14%
ROIC(3y)N/A
ROIC(5y)N/A
TNGX Yearly ROA, ROE, ROICTNGX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

  • TNGX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TNGX Yearly Profit, Operating, Gross MarginsTNGX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. TNGX Health Analysis

2.1 Basic Checks

  • TNGX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, TNGX has more shares outstanding
  • There is no outstanding debt for TNGX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
TNGX Yearly Shares OutstandingTNGX Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
TNGX Yearly Total Debt VS Total AssetsTNGX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

  • An Altman-Z score of 15.56 indicates that TNGX is not in any danger for bankruptcy at the moment.
  • TNGX's Altman-Z score of 15.56 is amongst the best of the industry. TNGX outperforms 86.92% of its industry peers.
  • There is no outstanding debt for TNGX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 15.56
ROIC/WACCN/A
WACC8.7%
TNGX Yearly LT Debt VS Equity VS FCFTNGX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

  • TNGX has a Current Ratio of 8.88. This indicates that TNGX is financially healthy and has no problem in meeting its short term obligations.
  • TNGX has a better Current ratio (8.88) than 76.92% of its industry peers.
  • TNGX has a Quick Ratio of 8.88. This indicates that TNGX is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of TNGX (8.88) is better than 76.92% of its industry peers.
Industry RankSector Rank
Current Ratio 8.88
Quick Ratio 8.88
TNGX Yearly Current Assets VS Current LiabilitesTNGX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. TNGX Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 22.03% over the past year.
  • Looking at the last year, TNGX shows a very strong growth in Revenue. The Revenue has grown by 53.28%.
  • The Revenue has been growing slightly by 4.34% on average over the past years.
EPS 1Y (TTM)22.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%151.85%
Revenue 1Y (TTM)53.28%
Revenue growth 3Y4.34%
Revenue growth 5YN/A
Sales Q2Q%363.61%

3.2 Future

  • Based on estimates for the next years, TNGX will show a small growth in Earnings Per Share. The EPS will grow by 4.02% on average per year.
  • TNGX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 34.29% yearly.
EPS Next Y24.98%
EPS Next 2Y-2.76%
EPS Next 3Y-5.68%
EPS Next 5Y4.02%
Revenue Next Year37.5%
Revenue Next 2Y-50.45%
Revenue Next 3Y-34.62%
Revenue Next 5Y34.29%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
TNGX Yearly Revenue VS EstimatesTNGX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
TNGX Yearly EPS VS EstimatesTNGX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 1 -1 2

More info and screens

Find the best growth stocksShow best growing peers

0

4. TNGX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for TNGX. In the last year negative earnings were reported.
  • Also next year TNGX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TNGX Price Earnings VS Forward Price EarningsTNGX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TNGX Per share dataTNGX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

  • TNGX's earnings are expected to decrease with -5.68% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.76%
EPS Next 3Y-5.68%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TNGX Dividend Analysis

5.1 Amount

  • No dividends for TNGX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TNGX Fundamentals: All Metrics, Ratios and Statistics

TANGO THERAPEUTICS INC

NASDAQ:TNGX (3/4/2026, 8:00:01 PM)

After market: 12.35 0 (0%)

12.35

+0.85 (+7.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04
Earnings (Next)03-05
Inst Owners96.96%
Inst Owner Change17.19%
Ins Owners1.26%
Ins Owner Change-4.26%
Market Cap1.66B
Revenue(TTM)66.50M
Net Income(TTM)-100.52M
Analysts85.88
Price Target15.19 (23%)
Short Float %35.66%
Short Ratio15.47
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)180.71%
Min EPS beat(2)1.36%
Max EPS beat(2)360.05%
EPS beat(4)2
Avg EPS beat(4)89.82%
Min EPS beat(4)-1.28%
Max EPS beat(4)360.05%
EPS beat(8)4
Avg EPS beat(8)49.54%
EPS beat(12)8
Avg EPS beat(12)40.29%
EPS beat(16)10
Avg EPS beat(16)31.6%
Revenue beat(2)1
Avg Revenue beat(2)-5.63%
Min Revenue beat(2)-53.3%
Max Revenue beat(2)42.04%
Revenue beat(4)1
Avg Revenue beat(4)-20.08%
Min Revenue beat(4)-53.3%
Max Revenue beat(4)42.04%
Revenue beat(8)3
Avg Revenue beat(8)10.95%
Revenue beat(12)5
Avg Revenue beat(12)18.27%
Revenue beat(16)6
Avg Revenue beat(16)14.08%
PT rev (1m)14.53%
PT rev (3m)21.54%
EPS NQ rev (1m)0.69%
EPS NQ rev (3m)2.29%
EPS NY rev (1m)0.12%
EPS NY rev (3m)18.21%
Revenue NQ rev (1m)-20%
Revenue NQ rev (3m)-30%
Revenue NY rev (1m)-0.11%
Revenue NY rev (3m)26.76%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 24.99
P/FCF N/A
P/OCF N/A
P/B 10.39
P/tB 10.39
EV/EBITDA N/A
EPS(TTM)-0.92
EYN/A
EPS(NY)-1.28
Fwd EYN/A
FCF(TTM)-1.09
FCFYN/A
OCF(TTM)-1.08
OCFYN/A
SpS0.49
BVpS1.19
TBVpS1.19
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -47.83%
ROE -62.81%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-30.42%
ROA(5y)-20.6%
ROE(3y)-49.57%
ROE(5y)-33.14%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 39.22%
Cap/Sales 1.43%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.88
Quick Ratio 8.88
Altman-Z 15.56
F-Score4
WACC8.7%
ROIC/WACCN/A
Cap/Depr(3y)190.33%
Cap/Depr(5y)N/A
Cap/Sales(3y)12.3%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%151.85%
EPS Next Y24.98%
EPS Next 2Y-2.76%
EPS Next 3Y-5.68%
EPS Next 5Y4.02%
Revenue 1Y (TTM)53.28%
Revenue growth 3Y4.34%
Revenue growth 5YN/A
Sales Q2Q%363.61%
Revenue Next Year37.5%
Revenue Next 2Y-50.45%
Revenue Next 3Y-34.62%
Revenue Next 5Y34.29%
EBIT growth 1Y21.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year25.65%
EBIT Next 3Y-14.03%
EBIT Next 5Y-2.16%
FCF growth 1Y-21.16%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-22.75%
OCF growth 3YN/A
OCF growth 5YN/A

TANGO THERAPEUTICS INC / TNGX FAQ

What is the ChartMill fundamental rating of TANGO THERAPEUTICS INC (TNGX) stock?

ChartMill assigns a fundamental rating of 4 / 10 to TNGX.


What is the valuation status of TANGO THERAPEUTICS INC (TNGX) stock?

ChartMill assigns a valuation rating of 0 / 10 to TANGO THERAPEUTICS INC (TNGX). This can be considered as Overvalued.


What is the profitability of TNGX stock?

TANGO THERAPEUTICS INC (TNGX) has a profitability rating of 1 / 10.